Podcasts about Exact sciences

PhD to Corporate Finance & M&A? Gabriel Fung's Unconventional Journey!Ever wondered how a PhD in Pathology transitions to high-stakes roles in Equity Research and Corporate Development? In this episode of Careers in Finance on FinPod, Gabriel Fung reveals his unique path from the lab to leading strategic M&A and partnerships at Exact Sciences in the competitive healthcare and biotech sectors. This is a must-listen for PhDs, scientists, and anyone considering a career pivot into finance from a non-traditional background!

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

In today's episode, supported by Exact Sciences, we had the pleasure of speaking with Eric Christenson, MD, about the Oncodetect test, which is available for use in molecular residual disease detection in patients with solid tumors. Dr Christenson is an assistant professor of oncology at the Johns Hopkins School of Medicine in Baltimore, Maryland. In our exclusive interview, Dr Christenson discussed the capabilities of Oncodetect, its clinical applications, key findings from the Alpha-CORRECT study, and the prognostic value of this test.

Die Diagnose Brustkrebs trifft jedes Jahr zehntausende Frauen wie ein Schock. Mehr als 70.000 Neuerkrankungen werden jährlich in Deutschland registriert; es handelt sich damit um die häufigste Krebsform bei Frauen und insgesamt die dritthäufigste Art von Krebs. Es gibt jedoch eine Vielzahl von Behandlungsmöglichkeiten, die im Idealfall möglichst individuell auf die einzelne Patientin zugeschnitten sind.

As the Gut Doctor podcast continues to raise awareness for colorectal cancer, Dr. Parikh interviews Dr. Paul Limburg, MD, who is a gastroenterologist and chief medical officer for Exact Sciences. They discuss colon cancer prevalence, barriers to CRC screening, and the role of stool based testing such as Cologuard. This episode is sponsored by Exact Sciences whose purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Exact Sciences is the maker of the Cologuard® test, a stool-based screening test for average risk adults ages 45 and over. 

How is France navigating and influencing today's complex geopolitical landscape? What strategy is President Macron deploying to end war in Europe? How do France and Norway collaborate on key global challenges? How is France leveraging AI to support its goals? Listen to the conversation with: Florence Robine, the French Ambassador to Norway Paal Frisvold, expert on European Affairs in Norway Mette Vågnes Eriksen, Secretary General, the Norwegian Polytechnic Society In this episode, you will gain insight to France's key priorities for strengthening European cooperation and the NATO alliance. You will hear practical examples from both the civil and military sectors, covering energy, the Arctic, and security. The participants also reflect on the actions of President Macron, one of the world's most influential heads of state and Europe's most-followed leader on social media. Additionally, you will discover how the French Navy helps safeguard Norwegian waters and explore the rich trade and cultural ties between our two nations. Get to know Ambassador Florence Robine, who holds a PhD in Epistemology and the History of Exact Sciences and Scientific Institutions. She has been awarded the prestigious French Legion of Honour and serves as an Associate Professor of Physical Sciences. A true Ambassadrice Polytechnique. Hosted on Acast. See acast.com/privacy for more information.

In this podcast episode, Prateek Sharma, MD, about how program directors can help shepherd GI fellows into clinical research spaces, providing quality exams for upper endoscopy and more. •    Intro :24 •    The interview/about Sharma :43 •    Tell us about your family and where you grew up. 1:00 •    Did you encourage your son to go into medicine? 2:17 •    What kinds of doctors were your parents?  3:40 •    Who were your big, early influences? 4:08 •    If you didn't always want to be a doctor, what convinced you to change your mind?  6:11 •    When did you make the decision to go into academic medicine as a career? 7:16 •    Are you seeing fewer and fewer fellows interested in pursuing a career in academic medicine? […] Are there ways to counsel fellows to be more interested in this type of work? 9:49 •    How long have you been a program director, and are you still enjoying the work? 13:58 •    How did you choose to into internal medicine and GI?  17:22 •    As leaders of academic research centers, what have you done or plan to do in the face of potential cuts to the NIH overhead rates? 18:40 •    How are we doing right now as a country and globally in terms of early detection of Barrett's neoplasia? 22:08 •    Why has performing high-quality surveillance and screening of procedures like colonoscopy been so much more successful than performing high-quality exams for upper endoscopy? 25:33 •    If the biggest hurdle to performing these exams is time, do you feel that more education around how to perform a high-quality exam will move the needle, or are other incentives needed? 28:32 •    Do you think AI-based detection is overhyped or underhyped in GI? 30:33 •    What are your thoughts on DNA-based testing for conditions like Barrett's neoplasia, and how should they be incorporated into standard practice? 34:24 •    What are your priorities as president of the American Society of Gastrointestinal Endoscopy this year? 38:42 •    What do you see as the biggest threats or concerns to gastroenterologists? 42:25 •    Final thoughts? 46:32 •    Thank you, Prateek 47:13 •    Thanks for listening 47:15 Prateek Sharma, MD, FASGE, FACP, FACG, is professor of medicine and director of the GI fellowship program at the University of Kansas School of Medicine. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Sharma, follow @KUcancercenter and @ASGEendoscopy on X and Instagram. Disclosures: Berry and Chey report no relevant financial disclosures. Sharma reports consulting for Boston Scientific Corporation, CDx Labs, Cipla, Exact Sciences, Medtronic, Olympus Corporation, Salix Pharmaceuticals, Samsung Bioepis and Takeda and provides grant/research support to ERBE USA Inc., Fujifilm Holdings America Corporation, Ironwood Pharmaceuticals Inc. and NEC.

Join us as we navigate the evolving landscape of colorectal cancer (CRC ) screening. In this episode, our expert faculty Drs. Wendy Wright and Roseann Velez delve into the critical importance of early CRC detection — especially in younger patients. We'll explore the latest expert consensus guidelines, the array of screening tests available and the barriers to effective screening. With robust data and real-world insights, this podcast aims to empower nurse practitioners with knowledge and tools to improve CRC screening uptake and outcomes. Tune in to learn how proactive screening can save lives and reduce the burden of CRC. To claim 1.0 contact hours of continuing education (CE) credit for this program, (Early Detection Saves Lives: Navigating the Evolving Landscape of Colorectal Cancer Screening), search for this program by the title and complete the post-test and evaluation by entering the participation code given after listening to the podcast. This podcast was supported by an independent medical education grant from Exact Sciences. Download the patient handout here

In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the OncoExTra® test from Exact Sciences, which includes whole-exome DNA sequencing and whole-transcriptome RNA sequencing, and how the latest updates to industry guidelines will continue to influence approaches to cancer care.

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.  Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

In healthcare marketing, product and marketing are inseparable. But in many industries, marketers have become disconnected from the products they promote. What does this mean for marketing effectiveness?Exact Sciences CMO Jaime LaMontagne joins Elena and Angela to explore how staying connected to product drives better marketing outcomes. Drawing from her extensive healthcare marketing experience, Jaime shares advice on balancing multiple stakeholders, strict regulations, and evolving patient expectations.Topics covered: [01:00] Why healthcare marketers must understand their products deeply[06:00] Using claims matrices to communicate with different stakeholders[14:00] Balancing creative marketing with healthcare regulations[18:00] How patient empowerment is changing healthcare marketing[23:00] The importance of both brand building and demand capture[30:00] Why marketers should "call their baby ugly"  To learn more, visit marketingarchitects.com/podcast or subscribe to our newsletter at marketingarchitects.com/newsletter.  Resources: 2024 MarketingWeek Article: https://www.marketingweek.com/ritson-liquid-death-product/Jaime LaMontagne's LinkedIn: https://www.linkedin.com/in/jaime-lamontagne-marketing100/Exact Sciences: https://www.exactsciences.com/ Get more research-backed marketing strategies by ubscribing to The Marketing Architects on Apple Podcasts, Spotify, or wherever you listen to podcasts.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

Our guest, Raye Arce with Exact Sciences joins us today as we discuss Colon Cancer or Colorectal Cancer. We will explore the various screening options available, including the non-invasive, at-home testing and the traditional colonoscopy. Ray will unpack the key factors influencing these choices, such as frequency, patient preferences, and the importance of early detection, which significantly improves survival rates. Additionally, Ray will provide insights into overcoming the barriers to screening and emphasize the importance of shared decision-making with healthcare providers. Tune in as we discuss how regular screening can make a life-saving difference and what you need to know to take charge of your health. Website: https://www. exactsciences.com SeniorLivingGuide.com Podcast sponsored by TransMed Care Long Distance Medical Transportation The background music is written, performed and produced exclusively by purple-planet.com.https://www.purple-planet.com/ *SeniorLivingGuide.com Webinars and Podcast represents the opinions and expertise of our guests. The content here is for informational and educational purposes. It does not necessarily represent the views, recommendations, opinions or advice of Fairfax Publishing/SeniorLivingGuide.com or its employees 

Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. He explains who may be eligible for these tests, how to interpret results to avoid unnecessary intervention from over-detection, and the varying sensitivity levels of MCED tests across different cancers. Additionally, Tom shares insights into the Falcon trial – a major real-world study assessing a MCED test clinical performance and potential impact on early cancer detection and patient outcomes. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Episode Summary:In this episode, Maribel Lopez speaks with Roni Jamesmeyer about the changing role of AI in healthcare. Roni Jamesmeyer, the the Senior Healthcare Marketing Manager for Five9, has over twenty years of experience in IT sales, giving her an understanding of the complexity of healthcare delivery. She focuses on Five9's healthcare strategy to help health systems, payers, and life sciences move their contact centers to the cloud and close the gaps in patient communications. Maribel and Roni discuss technological advancements in AI, different uses of AI in healthcare, and Roni's research findings.Key Themes:Maribel and Roni open the episode by discussing the healthcare industry's past attempts to improve the patient experience and how its goals have shifted. Currently, Roni is seeing healthcare companies working toward an omnichannel experience for their customers – meaning that they can interact over many communication channels. AI is helping the industry move forward. Intelligent Virtual Agents (IVAs) improve operations in four major ways: security, patient experience, revenue generation, and reduced administrative backend work. Different companies may focus more on some of these categories than others, but all four functions are extremely important to the healthcare industry. Roni also discusses her AI research findings. She found that AI tuning is crucial to improvement, allowing models to pick up and retain information. As these models are used, they become more personalized and more intelligent and can take on more work as a result. She also found that AI agents open up phone lines, allowing previously missed calls to be answered. Visit Maribel Lopez's Website: https://www.lopezresearch.com/ Follow Maribel Lopez on X/Twitter: https://x.com/maribellopez Subscribe to Maribel Lopez on YouTube: https://www.youtube.com/c/MaribelLopezResearch Follow Maribel Lopez on LinkedIn: https://www.linkedin.com/in/maribellopez/ Learn More About Five9: https://www.five9.com/ Download AI in Healthcare: How AI Drives Value for Five9 Customers: https://www.five9.com/resources/ebook/how-ai-drives-value-healthcare-customers#:~:text=Partners-,AI%20in%20Healthcare%3A%20How%20AI%20Drives%20Value%20For%20Five9%20Healthcare,customer%20surveys%2C%20and%20analyst%20insight. Attend Roni's Webinar with Exact Sciences: https://www.five9.com/registration/2024/exact-sciences-webinar Follow Roni Jamesmeyer on LinkedIn: https://www.linkedin.com/in/roni-jamesmeyer-5733461/ 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Delays in clinical trials can cost up to $8 million per day, making it crucial to understand and address the main factors causing these setbacks. Strategies to keep clinical trials on schedule include identifying common issues that slow down studies, addressing challenges effectively to minimize risks, and understanding potential financial losses to avoid them. By taking control of clinical trial timelines, researchers can prevent costly delays and ensure successful completion of studies.Senseonics has received FDA clearance for a continuous glucose monitoring (CGM) device that can be worn for up to 365 days. Boston Scientific has closed its acquisition of Silk Road Medical, while Smiths Medical has recalled airway tubes due to a defect that has caused more than 10 injuries. Medtech firms have cut over 14,000 jobs in the past 18 months. Exact Sciences has announced that data supports its colon cancer blood test, which could compete with Guardant Health's similar test. Bausch + Lomb is considering a sale, with private equity firms being potential buyers. The wearables market is expected to grow by 13% annually between 2024 and 2030.Merck's ADC data shows promising results in a lung cancer trial, while Ascendis' trial data puts pressure on Biomarin. Nura Bio secures $68 million in funding for neuroprotective brain drugs. The Biosecure bill could lead to drugmakers pivoting towards China. ESMO24 highlights include a cancer cachexia drug and the impact of immunotherapy on survival rates. Drug development leaders are turning to AI to drive efficiency.Cigna is suing the FTC over a report on pharmacy benefit managers, while employer health costs are expected to rise by 5.8% per employee in 2025. Johns Hopkins has appointed a new cybersecurity chief, and healthcare worker strikes are being tracked, such as nurses at Brigham and Women's Faulkner Hospital planning a strike. Employers are making cost-cutting changes to health plans, and the impact of mentorship in healthcare is highlighted.Pizza Hut is using its pizza boxes to help job seekers get noticed by putting resumes on them. Frito-Lay's campaign targeted at Gen Zers encourages fans to cheat on Flamin' Hot Cheetos with other brands. The US ad spending rebound is proving to be robust beyond cyclical events, such as the Olympics. However, customers don't trust AI, which could be hurting businesses as it decreases purchasing intention.The pharmaceutical industry is facing challenges in expanding patient access and improving cancer research outcomes. Compassionate use, also known as expanded access, provides unapproved drugs to terminally ill patients as a last resort. Radiopharmaceuticals have seen a resurgence in activity and interest from big pharma for treating cancer. Ratio Therapeutics advocates for compassionate use due to the low-risk, high-reward nature of radiopharmaceuticals. Despite challenges like patient safety and ongoing clinical trials, radiopharmaceuticals are gaining momentum in the industry. Big pharma companies are embracing this trend, with smaller players also making waves in the market. The industry is exploring strategies for better site selection in clinical trials and enhancing efficiency during gene therapy development.

In this second part of our discussion, we delve deeper into the innovative approaches and technologies being implemented to address the evolving challenges in cancer care. Panelists will share their experiences with AI-powered tools, virtual reality applications, and personalized treatment plans. We'll also explore the role of patient advocacy in shaping the future of cancer care and the importance of collaboration between healthcare providers, researchers, and technology companies.This episode is sponsored by Exact Sciences.

This podcast discusses the increasing challenges faced by healthcare organizations in providing cancer care due to rising patient numbers and complex treatment needs. Panelists share their experiences and strategies for addressing these challenges, including leveraging technology, expanding access to care, and prioritizing patient advocacy. The discussion also highlights the importance of a collaborative approach between healthcare providers and technology companies to improve patient outcomes. This episode is sponsored by Exact Sciences.

New opportunities are emerging for dedicated biomarker testing navigators facilitated by laboratory professionals to better streamline sample collection and optimize test ordering and results for patients with cancer. In this episode, CANCER BUZZ TV speaks with Lynnette Pineault, MBA, SCT (ASCP), chair of the American Society for Clinical Pathology (ASCP) Biomarker Testing Navigation Feasibility Study and manager of Laboratory Operations and Genetic Counseling Services, Medical Library and Pathology Services, at HealthPartners – Regions Hospital, who shares insights on reshaping multidisciplinary cancer care team workflows to enable laboratory professionals to improve biomarker testing efficiency. “We see these roles [dedicated biomarker testing navigators] playing across and matrixing to support the sample [biomarker testing specimen] along its pathway, so the patient and the sample get to their destination and their treatment/follow-up at the appropriate times together.”—Lynnette Pineault, MBA, SCT (ASCP) Lynnette Pineault, MBA, SCT (ASCP) Chair, ASCP Biomarker Testing Navigation Feasibility StudyManager, Laboratory Operations and Genetic Counseling Services Laboratory Medicine and Pathology Services HealthPartners – Regions Hospital St. Paul, MN   This video podcast was produced in partnership with the American Society for Clinical Pathology and by support from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Exact Sciences, and Merck.    Resources: ASCP Explores Innovative Cancer Biomarker Testing Navigator Role (criticalvalues.org) ACCC Cancer Diagnostics Education Program Precision Medicine Stewardship (accc-cancer.org)  

Bryan Goettel is the director of advocacy and alliance relations for Exact Sciences, a Madison, Wisconsin, based biotechnology company. Exact Sciences is perhaps best known for its signature product, Cologuard, an at-home colorectal cancer early detection test for adults of average risk age 45 and older. Further Together host Michael Holtz has a history with the company, including sharing his cancer journey at the first-ever national sales meeting for Cologuard in July 2014 and attending the Cologuard Classic golf tournament as a cancer advocate this past spring. Exact Sciences is on the forefront of oncology treatment and cancer prevention. During this conversation, Goettel talks about where Exact Sciences is heading in the biotechnology space, how he got to be part of the company, the importance of the patient voice in shaping its products, and how companies like ORAU can join the fight against cancer. To learn more, visit https://www.exactsciences.com/

In this podcast episode, John Inadomi, MD, chair of the department of internal medicine at University of Utah Health, discusses the value of mentorship, qualities a leader should possess and more. •    Intro :59 •    Welcome to this episode of Gut Talk 1:23 •    The interview/about Inadomi 1:30 •    Tell us about your family and where you grew up. 2:59 •    Inadomi on the impact World War II had on his family. 3:47 •    Chey and Inadomi on the ways immigrants approached being American post-World War II. 4:33 •    How did you end up in medicine after receiving a mechanical engineering degree from MIT?  6:32 •    How did you go from bionics to polyps/GI? 8:00 •    What did you learn from your experiences playing water polo in college? 10:31 •    How did you end up at the University of New Mexico? 13:00 •    What did Amnon Sonnenberg, MD, MSc, teach you? 16:04   •    How do you view and embrace change? 18:27 •    When did you catch the bug of wanting to lead faculty? […] Did you have mentorship specifically on health system leadership? 24:30 •    How have you learned these leadership characteristics and skills that are not an inherent part of physician training? Do you think there is going to be a change in leadership development moving forward? 29:59 •    For people thinking about advancement opportunities in leadership, what is the mindset you have to develop as a successful division chief or a successful department chair? 33:55 •    What do you think are the biggest challenges facing academic gastroenterology or academic internal medicine? […] How can we physicians be aware of and mitigate these challenges? 38:36 •    How are academic medical centers going to survive?  41:39 •    Do you see the loss of physician autonomy and burnout getting better? 43:29 •    What has been your favorite golf course that you have played on? 46:36 •    Thank you, John 47:48 •    Thanks for listening 48:14 John M. Inadomi, MD, is the Jon M. Huntsman presidential endowed chair, and the chair of the department of internal medicine at University of Utah Health. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Inadomi, follow him on X @InadomiJ. Disclosures: Berry and Chey report no relevant financial disclosures. Inadomi reports grant support from Exact Sciences.

Learn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs. =============== Dr. Maria Abunto is the Senior Manager of Medical Science Liaisons at Exact Sciences, a molecular diagnostics company specializing in the detection of early-stage cancers. Before that, she was a Global Medical Science Liaison for Stryker. She previously worked as an epidemiologist and investigator for the NIH and as a medical scientific expert on the IRB at a large children's hospital. She holds a master's degree in public health from the University of Pittsburg and completed her medical degree at the University of the East in Manila, Philippines. Maria has been an active member of the Medical Science Liaison Society, and mentors other physicians interested in pursuing jobs as an MSL. She frequently lectures on the topic. Because of her expertise, she was asked to present at the 2023 Nonclinical Career Summit on this topic. Today's podcast episode is an excerpt from that lecture. In it, she describes the duties of an MSL, the pros and cons of the job, the salary to be expected, and tips for pursuing your first position as an MSL. You will find all of the links mentioned in the episode at https://nonclinicalphysicians.com/first-nonclinical-msl-job/

Dr. Travelle Franklin-Ford Ellis, talks about her extraordinary shift from an MD/PhD candidate to a vanguard of health equity at Exact Sciences.Dr. Nii and Dr. Travelle talk about:Not matching into residency even with an MD/PhD.10 years of medical school and ending up not practicing on patients.What next after not matching?Advice to premeds who are trying to figure it out.Taking risks in medicine.SIGN UP FOR OUR NEWSLETTER! Have a question for the podcast?Text us at 833-230-2860Send us a message HERE! Twitter: @drniidarkoInstagram: @docsoutsidetheboxEmail: team@drniidarko.comPodcasting Course: www.docswhopodcast.comMerch: https://docs-outside-the-box.creator-spring.comThis episode is sponsored by Locumstory. Learn how locum tenens helps doctors make more and have the lifestyle they deserve!. Check them out HERE!

In this episode of the show, we explore the concept of purposeful branding in healthcare technology and its potential to drive both business success and positive change. Our guests, Steffany Whiting, Executive Vice President of Marketing at iMethods, and Matthew Piette, former Head of Brand Marketing at Exact Sciences and Director of Brand for Philips, share their insights and experiences in building and maintaining purposeful brands in the healthcare industry. In this episode we cover: Defining purposeful branding and its unique application in healthcare How iMethods has built a strong purposeful brand and the impact it has had on their business Innovative programs for engaging employees in a company's mission Challenges of embedding a purposeful culture in larger organizations Making brand purpose real and measurable through patient testimonial videos and measurable goals The ROI of a meaningful mission The role of individual employees in becoming purposeful brand ambassadors Advice for healthcare technology marketers looking to embrace purposeful branding Steffany delves into how iMethods has built a strong, purposeful brand by focusing on changing lives, serving the community, and living out its core values. She discusses the impact this approach has had on employee retention, client loyalty, and business growth, and shares some of the innovative programs iMethods has implemented to engage employees in the company's mission. Matthew brings his experience from larger organizations, discussing the challenges of embedding a purposeful culture in these companies and the importance of senior leadership understanding and communicating the brand's purpose. He also shares examples of how Exact Sciences and Philips have made their brand purpose real and measurable through patient testimonial videos and measurable goals. Together, Steffany and Matthew offer valuable insights and advice for healthcare technology marketers looking to embrace purposeful branding in their organizations. They discuss the unique application of this concept in healthcare, the ROI of a meaningful mission, and the role of individual employees in becoming purposeful brand ambassadors. This episode is a must-listen for anyone interested in the power of purposeful branding to drive both business success and positive change in healthcare.

In this MM+M Fast Break, Jack O'Brien talks with former NBA All Star and Kentucky Wildcats legend Jamal Mashburn about working with Exact Sciences on the company's Box Out Colon Cancer campaign.He discusses his personal connection to colorectal cancer, his involvement in the awareness push and his Final Four predictions.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries.    “There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW   Hilary Gee Goeckner, MSW Director, State and Local Campaigns, Access to Care American Cancer Society Cancer Action Network Washington, D.C. This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences. Resources: The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions  Comprehensive Cancer Care: The Role of Biomarker Testing  Biomarker Testing for Medicaid Beneficiaries (Podcast)  Access to Biomarker Testing - American Cancer Society Cancer Action Network   The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog  Improving Access to Biomarker Testing in Medicaid Populations  Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog  Patient Perceptions of Biomarker Testing – Oncology Issues  Cancer Diagnostics - Biomarkers  Eliminating Precision Medicine Disparities    

Welcome to Off The Tap! Join us this week as we drink Dublin Me Luck brewed at 11 Below Brewing Company in Houston, Texas and discuss topics like St. Patrick's Day Do's & Don'ts, Exact Sciences, “As Seen on TV”, and more. If you enjoy the content, follow us on social media to watch clips and stay up to date on episode releases! Twitter: @offthetappod Instagram: @offthetappodcast TikTok: @offthetappod Facebook: @offthetappodcast

Are you ready to level up and learn from uncomfortable experiences? In this episode of the HR Mixtape podcast, host Shari Simpson is joined by guest Kyra Matkovich to tackle some juicy HR questions sourced from the internet. They discuss topics such as addressing discrepancies in employee information, renaming holiday events for inclusivity, dealing with condescending behavior from a C-suite leader, handling an employee with a drinking problem, and navigating a challenging relationship with an internal candidate. Three key takeaways from this episode are: When addressing discrepancies in employee information, it's important to approach the conversation with sensitivity and offer support rather than make assumptions or judgments. Inclusive language and renaming events can help create a more welcoming and inclusive workplace environment, especially when it comes to holiday celebrations. Dealing with challenging behavior from a C-suite leader requires open and honest communication, setting clear expectations, and documenting any inappropriate incidents. It's crucial to prioritize the well-being of employees and hold leaders accountable for their actions. Overall, this episode provides valuable insights and practical advice for HR professionals facing various HR challenges in the workplace. Guest(s): Kyra Matkovich, Principal Human Resources Business Partner, Exact Sciences

Welcome to Becker's Healthcare Podcast, where we delve into the fascinating world of genetic counseling in oncology. Sponsored by Exact Sciences, this episode features Megan Inger, a licensed certified genetic counselor specializing in oncology at Ohio Health. Megan discusses her journey into genetic counseling, emphasizing the profound connections she forms with patients. She highlights the pivotal role genetic counselors play in identifying individuals for genetic testing, interpreting complex results, and supporting patients throughout their cancer journey. Megan also explores the transformative impact of comprehensive genomic profiling on cancer care, sharing real-life examples where genetic knowledge altered lives. Join us in unlocking the empowering role of genetic counseling in oncology decisions with Megan Inger on this insightful episode.This episode is sponsored by Exact Sciences.

November 22: Today on the Conference channel, it's an Interview in Action live from the 2023 CHIME Fall Forum. On this episode Sue Schade, Principal at StarBridge Advisors speaks with Cherodeep Goswami, Chief Information & Digital Officer at The University of Wisconsin Health System and Nassar Nizami, Chief Information Officer at Exact Sciences. What's in store for Exact Sciences, a renowned clinical research company mainly known for their product ColoGuard? How is UW Health working towards deploying automation?Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics.  Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.   Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products. Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer. Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies. Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices. Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.

Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023

In this episode of Meeting Mic, we bring you Healio's top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.

Welcome to Life in the Leadership Lane where I am talking to leaders making a difference in the workplace and in our communities. How did they get to where they are and what are they doing to stay there! Buckle up and get ready to accelerate in the Leadership Lane! This week, I am talking with Kyra Matkovich, SHRM-CP, PHR, Principal Human Resources Business Partner at Exact Sciences. How did Kyra get started in her career? What led her to the world of HR and Leadership? What does Kyra share about mentors that have inspired her journey? When did Kyra “find her lane” in her career? What does Kyra share about “HR Coffee Shot”? What does Kyra share about “leadership”? What does Kyra share about the importance of "laughter”? What does Kyra share about being intentional? What does Kyra share about “HR Shenanigans”? What does Kyra share about volunteer leadership? What advice does Kyra share to help us in our every day? …and more as we spend “Time to Accelerate” with a few more questions. Interview resources: Favorite quote(s) from Kyra: “The greatest resources you have are the people around you.” “Laughter is a way we connect with people.” Connect with Kyra on LinkedIn Learn more about Kyra's Blog here HR Shenanigans Check out Bruce's books Life in the Leadership Lane; Moving Leaders to Inspire and Change the Workplace Find Your Lane; Change your GPS, Change your Career (“Book Authority” Best Books) Milemarkers; A 5 Year Journey …helping you record daily highlights to keep you on track. Subscribe to Bruce's Blog “Move to Inspire” Connect with Bruce on LinkedIn Connect with Bruce on Twitter Connect with Bruce on Instagram Connect with Bruce on Facebook Get relocation support for your next household goods or commercial office move across the US by reaching out to Bruce at bwaller@goarmstrong.com or visit The Armstrong Company

The National Native Network and Exact Sciences present a webinar. Title: Colorectal Cancer Risk Reduction in Indian Country Date: Wednesday, August 30, 2023 Presenters: Travelle Ellis, MD, PhD Health Equity Director Exact Sciences Emily Ferroni, M.S. Patient Navigator at Little Traverse Bay Bands of Odawa Indians Inter-Tribal Council of Michigan Learning Objectives/Outcomes: At the conclusion of this activity, the healthcare team will be able to: 1. Differentiate CRC screening modalities 2. Identify when to offer a multi-targeted stool DNA test. 3. Evaluate how the patient assistance programs work to promote accessible CRC screening in AI/AN communities. Target Audience: Physicians, nurses, health educators, administrators, and support staff working with American Indian and/or Alaska Native communities. Funding for this webinar was made possible by the Centers for Disease Control and Prevention DP18-1808: Networking2Save: CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations. Webinar contents do not necessarily represent the official views of the Centers for Disease Control and Prevention, and the Indian Health Service, or the Department of Health and Human Services.

Exact Sciences Corporation, Q2 2023 Earnings Call, Aug 01, 2023

Join Dr. Rick Baehner, Chief Medical Officer of the Precision Oncologydivision at Exact Sciences, in this episode of Becker's Healthcare Podcast. Dr.Baehner discusses the evolving landscape of precision oncology and how ExactSciences is equipped to address the dynamic challenges and opportunities inmolecular testing for cancer patients. He shares key milestones that highlight thecompany's commitment to innovation. Exploring the role of technology in cancerprevention, early detection, and improved treatment guidance, Dr. Baehner explainshow Exact Sciences aligns with these objectives while addressing the concerns ofcancer leaders. Discover what exciting goals and developments are on the horizonfor Exact Sciences and tune in for Dr. Baehner's closing thoughts on this insightfuljourney.This episode is sponsored by Exact Sciences.Cologuard is intended to screen adults 45 and older at average risk for colorectalcancer. Rx only. Please see Cologuard Indications and Important Risk Information atCologuardhcp.com/risk-information. Exact Sciences' MCED and MRD tests are underdevelopment. The features discussed in this podcast describe current developmentgoals. It has not been cleared or approved by the US Food and Drug Administrationor any other national regulatory authority.

Sarah Condella, executive vice president of human resources at Exact Sciences, shares what creating a best-in-class workplace culture means for the customer experience and an engaged workforce.

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.

Stocks may be taking a breather after their recent run, but our special guest says she's more bullish on the market than she's been in a long time. She lays out her case and gives us her strategy. Plus shares of FedEx dropping after missing revenue estimates for its latest quarter. And the CEO of Exact Sciences on the company's latest colorectal cancer test results. Fast Money Disclaimer

Exact Sciences Corporation, Q1 2023 Earnings Call, May 09, 2023

This episode features Stephen Gruber, Vice President at City of Hope National Medical Center and Director of City of Hope's Center for Precision Medicine, Stacy Gray, Chief of City of Hope's Division of Clinical Cancer Genomics and Deputy Director of its Center for Precision Medicine, Sumanta “Monty” Pal, Co-Director of the Kidney Cancer Program at City of Hope, and Rick Baehner, M.D., Chief Medical Officer at Exact Sciences Precision Oncology. Here, they discuss their experience building their precision oncology program at City of Hope and how it has improved patient care and clinical outcomes across the organization.This episode is sponsored by Exact Sciences

Today, Tasha Keeney sits down with Simon Barnett to talk about ARK's valuation of Exact Sciences and to share our outlook about the company's trajectory in the next five years. Exact Sciences is the cancer testing company that has brought to market both Cologuard and Oncotype. This conversation covers the prominence and acceptance of these two testing franchises, Exact Sciences' product leadership, Exact's recent performance in the market, the models that ARK has developed for gauging the company's outlook, and the areas of risk that investors should be aware of. One of the main focuses of today's chat is what Exact Sciences' progress symbolizes in terms of the future of the cancer treatment field, with Simon making an argument for why he sees them holding onto their market-leading position for the foreseeable future. We also spend some time at the end of the episode considering what this means for healthcare and individual wellbeing in general, so make sure to catch it all in this episode of For Your Innovation! Please refer to the Exact Sciences valuation article for a more comprehensive explanation of ARK's model, including its risks and limitations. “Cancer care is something that is totally divorced from interest rate changes or consumer sentiment. It's something that's very predictable, and it's something that's very important.” — @sbarnettARK Key Points From This Episode: Introducing Exact Sciences and its two biggest testing franchises: Cologuard and Oncotype. Valuation of Exact Sciences and how ARK has approached creating these models. Calculations for the price target of the company. Sales and marketing at Exact Sciences and the positive brand recognition they have built. Benchmarks for analyzing companies like Exact Sciences. Comparing ARK's process and view on Exact Sciences to other opinions in the market. How the lowered price of genome sequencing has affected the outlook for the market. The route to the aggregate gross margin structure for Exact Sciences. Qualitative elements that matter most to ARK; how Exact Science fits into our rubric. Alignment between the expectations of Exact Science's management and our estimations. A look at the three main areas of risk: competition, time, and financing. Simon explains how thesis risk applies to the healthcare space. Thoughts on the company's net income and cash flow in the near future. Reasons to be excited about the next few years in the healthcare space.

On this episode of The Internship Show, we speak with Domonique Tucker from Exact Sciences. Domonique gives her advice to students on how to navigate the job search and what an intern at their company can expect during the program.

In this episode, we are joined by Dr. Tom Beer, Chief Medical Officer and Vice President, Multi-Cancer Early Detection at Exact Sciences, to discuss multi-cancer early detection (MCED) testing and how it is framing the future of cancer screening. Hear Dr. Beer's insights on if the United States has made enough progress in cancer detection and prevention, and the advances in science and technology that are making progress possible. Tune in to hear what we are learning from the early data in MCED testing, how MCED testing can close the gap in disparities in health equity, and Dr. Beer's thoughts on the implementation of effective MCED testing in the future for health systems. This episode is sponsored by Exact Sciences.